Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - The rapid growth of overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

Group 1 - The company announced the resignation of Mr. Haiteng Bai as non-executive director, honorary chairman, and member of the strategic committee effective September 30, 2025, to dedicate more time to other business activities [1] - Mr. Norihiro Adachi also resigned as non-executive director and member of the audit committee for similar reasons [1] - Dr. Gu Feng has been appointed as a non-executive director and member of the nomination and remuneration committees [1] Group 2 - Dr. Men Qingbing has been appointed as a non-executive director, member of the audit committee, and chairman of the strategic committee [1] - Dr. Chang Zhaohua is no longer a member of the remuneration committee and chairman of the strategic committee [1] - Mr. Zhou Jia Hong has been appointed as a member of the nomination committee [1]

Core Viewpoint - MicroPort Medical (00853.HK) announced the resignation of two non-executive directors, which may impact the company's strategic direction and governance structure [1] Group 1 - Taisuke Shiratani resigned as non-executive director, honorary chairman, and member of the company's strategic committee to focus more on other business activities [1] - Norihiro Adachi resigned as non-executive director and member of the company's audit committee for similar reasons [1]

Group 1 - The company announced the resignation of Mr. Haku Fujita as a non-executive director, honorary chairman, and member of the strategic committee effective September 30, 2025, to dedicate more time to other business activities [1] - Mr. Narihiro Arita also resigned as a non-executive director and member of the audit committee for similar reasons [1] - Dr. Gu Feng has been appointed as a non-executive director and member of the nomination and remuneration committees [1] Group 2 - Dr. Men Qingbing has been appointed as a non-executive director, member of the audit committee, and chairman of the strategic committee [1] - Dr. Chang Zhaohua is no longer a member of the remuneration committee and chairman of the strategic committee [1] - Mr. Zhou Jia Hong has been appointed as a member of the nomination committee [1]

微創醫療科學有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：00853） 於二零二五年十月二十二日（星期三）舉行的股東特別大會之代表委任表格 地址為 為本人╱吾等之代表，代表本人╱吾等出席本公司謹訂於二零二五年十月二十二日（星期三）上午十時正假座中華人民共和國上海市 張江高科技園區張東路1601號（郵編：201203）舉行的股東特別大會（及其任何續會），並代表本人╱吾等按以下指示投票。 請在適當空欄內標示「✔」號，以表示投票意願 （附註4） 。 | 特別決議案 | 贊成 | 反對 | | --- | --- | --- | | 動議批准及採納經第五次修訂及重訂的本公司組織章程大綱及組織章程細則（「新章程細 | | | | 則」）（其副本已向大會提交，並註明「A」及由大會主席簽署以供識別），以取代及摒除本公司 | | | | 現行組織章程大綱及組織章程細則，並於本公司公佈投票表決結果，即本決議案作為特別 | | | | 決議案已獲正式通過及本公司董事獲授權進行一切必要事項以實施採納新章程細則後即時 | | | | 生效。 | | | 日期：二零二五年 月 日 簽署 （附註5） 本代表委任表格相關股份 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 承董事會命 微創醫療科學有限公司* 主席 常兆華博士 中國上海，二零二五年九月三十日 * 僅供識別 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 股東特別大會通告 茲通告微創醫療科學有限公司（「本公司」）謹訂於二零二五年十月二十二日（星期三）上午十時正假座中 華人民共和國上海市張江高科技園區張東路1601號（郵編：201203）舉行股東特別大會（「股東特別大 會」），以處理下列事項： 考慮並酌情通過下列決議案為特別決議案： 「動議批准及採納經第五次修訂及重訂的本公司組織章程大綱及組織章程細則（「新章程細則」）（其副 本已向大會提交，並註明「A」及由大會主席簽署以供識別），以取代及摒除本公司現行組織章程大綱 及組織章程細則，並於本公司公佈投票表決結果，即本決議案作為特別決議案已獲正式通過及本公 司董事獲授權進行一切必要事項以實施採納新章程細則後即時生效。」 1 附註： ...

此乃要件 請即處理 閣下如對本通函任何方面或將予採取的行動有任何疑問，應諮詢股票經紀或其他註冊證券交易 商、銀行經理、法律顧問、專業會計師或其他專業顧問。 倘 閣下已將名下所有微創醫療科學有限公司的股份出售或轉讓，應立即將本通函連同隨附的 代表委任表格交予買主或承讓人，或交予經手買賣或轉讓的銀行、股票經紀或其他代理，以便 轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因倚 賴該等內容而導致的任何損失承擔任何責任。 | | | 釋義 | 1 | | --- | --- | --- | --- | | 董事會函件 | | | | | 1. 緒言 | | | 3 | | 2. | | 建議修訂組織章程細則 | 4 | | 3. | | 責任聲明書 | 5 | | 4. | | 股東特別大會及代表委任安排 | 5 | | 5. | | 推薦建議 | 6 | | 附錄 | － | 建議修訂組織章程細則 | 7 | | | | 股東特別大會通告 | 10 | 釋 義 微創醫療科學有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 董事名單與其角色及職能 微創醫療科學有限公司董事會（「董事會」）成員載列如下： 執行董事 周嘉鴻先生 劉國恩博士 邵春陽先生 1 董事會已成立四個委員會。該等委員會成員資料載列如下： 周嘉鴻先生 （主席） 邵春陽先生 周嘉鴻先生 門慶兵博士 谷峰博士 提名委員會 戰略委員會 邵春陽先生 （主席） 劉國恩博士 周嘉鴻先生 周嘉鴻先生 孫維琴女士 谷峰博士 孫維琴女士 常兆華博士 （主席） 非執行董事 谷峰博士 門慶兵博士 孫維琴女士 獨立非執行董事 主席 常兆華博士 中國上海，二零二五年九月三十日 * 僅供識別 審核委員會 薪酬委員會 劉國恩博士 （主席） 門慶兵博士 （主席） 承董事會命 微創醫療科學有限公司* 2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 董事及董事委員會組成之變動；及 建議採納新組織章程大綱及細則 本公告乃由微創醫療科學有限公司（「本公司」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則 （「上市規則」）第13.51(1)條及第13.51(2)條而作出。 董事及董事委員會組成之變動 本公司董事（「董事」）會（「董事會」）宣佈以下董事會及董事委員會之變動，自二零二五年九月三十日起 生效： 非執行董事辭任 1 (1) 谷峰博士（「谷博士」）已獲委任為非執行董事以及本公司提名委員會（「提名委員會」）及薪酬委員會 （「薪酬委員會」）成員。 谷博士於二零一一年八月取得同濟大學企業管理博士學位。 根據證券及期貨條例（「證券及期貨條例」）第XV部，谷博士於本公司或其任何相聯法團的任何股 份、相關股份或債權證中概無擁有或被視為擁有權益。 (1) 白藤泰司先生（「白藤 ...